Table 1. Clinical characteristics and quantitative parameters of patients with GBM and PCNSL.
| Clinical characteristics | GBM (n = 55) | PCNSL (n = 20) | p value |
|---|---|---|---|
| Age at diagnosis, mean ± SD | 66 ± 1.5 | 70 ± 8.7 | 0.34* |
| Sex, male/female | 33/22 | 9/11 | 0.30** |
| Enhancing lesion in MRI, n (%) | |||
| Single (%) | 40 (73%) | 10 (50%) | 0.096** |
| Multiple (%) | 15 (27%) | 10 (50%) | |
| Number of lesions, mean ± SD | 1.5 ± 1.1 | 2.3 ± 1.8 | 0.031* |
| Primary focus | |||
| Cerebral hemisphere | 49 (89.1%) | 10 (50%) | |
| Supratentorial central structures | 5 (9.1%) | 7 (35%) | |
| Cerebellar hemisphere | 0 | 2 (10%) | |
| Vermis | 1 (1.8%) | 1 (5%) | |
| Steroid administration prior to imaging | 11 (20%) | 8 (40%) | 0.13** |
| Quantitative parameters, mean ± SD | |||
| FDG-PET | |||
| SUVmax | 11.27 ± 4.21 | 25.78 ± 7.17 | 8.7 × 10–17* |
| T/N_SUVmax | 1.38 ± 0.63 | 2.95 ± 0.63 | 2.2 × 10–14* |
| ASL | |||
| Contralateral CBF | 63.27 ± 17.24 | 65.11 ± 21.75 | 0.704* |
| 1.5-T | 70.71 ± 15.90 (n = 17) | 83.97 ± 14.35 (n = 7) | |
| 3.0-T | 59.94 ± 16.95 (n = 38) | 54.95 ± 18.07 (n = 13) | |
| p value (1.5-T vs. 3.0-T) | 0.031* | 0.018* | |
| aTBFmax | 165.02 ± 79.87 | 96.38 ± 28.75 | 3.6 × 10–4* |
| 1.5-T | 198.45 ± 113.63 | 110.00 ± 17.72 | |
| 3.0-T | 150.06 ± 54.62 | 89.05 ± 31.39 | |
| p value | 0.037* | 0.12* | |
| rTBFmax | 2.71 ± 1.25 | 1.54 ± 0.44 | 1.1 × 10–4* |
| 1.5-T | 2.89 ± 1.66 | 1.32 ± 0.17 | |
| 3.0-T | 2.64 ± 1.03 | 1.66 ± 0.49 | |
| p value | 0.496* | 0.097* |
*Student’s t-test; **Fisher’s exact test.
ASL: arterial spin labeling, aTBFmax: absolute maximum tumor blood flow, CBF: cerebral blood flow, GBM: glioblastoma, MRI: magnetic resonance imaging, PCNSL: primary central nervous system lymphoma, rTBFmax: relative maximum tumor blood flow, SD: standard deviation, SUVmax: standardized uptake value, T/N: the ratio of tumor to normal contralateral gray matter.